Cargando…
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
BACKGROUND: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. METHODS: Sixteen partici...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851267/ https://www.ncbi.nlm.nih.gov/pubmed/26506856 http://dx.doi.org/10.1093/ijnp/pyv121 |
_version_ | 1782429794114207744 |
---|---|
author | Bioque, Miquel Llerena, Adrián Cabrera, Bibiana Mezquida, Gisela Lobo, Antonio González-Pinto, Ana Díaz-Caneja, Covadonga M. Corripio, Iluminada Aguilar, Eduardo J. Bulbena, Antoni Castro-Fornieles, Josefina Vieta, Eduard Lafuente, Amàlia Mas, Sergi Parellada, Mara Saiz-Ruiz, Jerónimo Cuesta, Manuel J. Bernardo, Miguel |
author_facet | Bioque, Miquel Llerena, Adrián Cabrera, Bibiana Mezquida, Gisela Lobo, Antonio González-Pinto, Ana Díaz-Caneja, Covadonga M. Corripio, Iluminada Aguilar, Eduardo J. Bulbena, Antoni Castro-Fornieles, Josefina Vieta, Eduard Lafuente, Amàlia Mas, Sergi Parellada, Mara Saiz-Ruiz, Jerónimo Cuesta, Manuel J. Bernardo, Miguel |
author_sort | Bioque, Miquel |
collection | PubMed |
description | BACKGROUND: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. METHODS: Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. RESULTS: The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). CONCLUSIONS: These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines. |
format | Online Article Text |
id | pubmed-4851267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48512672016-05-02 A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project Bioque, Miquel Llerena, Adrián Cabrera, Bibiana Mezquida, Gisela Lobo, Antonio González-Pinto, Ana Díaz-Caneja, Covadonga M. Corripio, Iluminada Aguilar, Eduardo J. Bulbena, Antoni Castro-Fornieles, Josefina Vieta, Eduard Lafuente, Amàlia Mas, Sergi Parellada, Mara Saiz-Ruiz, Jerónimo Cuesta, Manuel J. Bernardo, Miguel Int J Neuropsychopharmacol Research Article BACKGROUND: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. METHODS: Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. RESULTS: The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). CONCLUSIONS: These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines. Oxford University Press 2015-10-27 /pmc/articles/PMC4851267/ /pubmed/26506856 http://dx.doi.org/10.1093/ijnp/pyv121 Text en © The Author 2015. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bioque, Miquel Llerena, Adrián Cabrera, Bibiana Mezquida, Gisela Lobo, Antonio González-Pinto, Ana Díaz-Caneja, Covadonga M. Corripio, Iluminada Aguilar, Eduardo J. Bulbena, Antoni Castro-Fornieles, Josefina Vieta, Eduard Lafuente, Amàlia Mas, Sergi Parellada, Mara Saiz-Ruiz, Jerónimo Cuesta, Manuel J. Bernardo, Miguel A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project |
title | A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project |
title_full | A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project |
title_fullStr | A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project |
title_full_unstemmed | A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project |
title_short | A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project |
title_sort | pharmacovigilance study in first episode of psychosis: psychopharmacological interventions and safety profiles in the peps project |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851267/ https://www.ncbi.nlm.nih.gov/pubmed/26506856 http://dx.doi.org/10.1093/ijnp/pyv121 |
work_keys_str_mv | AT bioquemiquel apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT llerenaadrian apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT cabrerabibiana apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT mezquidagisela apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT loboantonio apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT gonzalezpintoana apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT diazcanejacovadongam apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT corripioiluminada apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT aguilareduardoj apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT bulbenaantoni apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT castrofornielesjosefina apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT vietaeduard apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT lafuenteamalia apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT massergi apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT parelladamara apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT saizruizjeronimo apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT cuestamanuelj apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT bernardomiguel apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT apharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT bioquemiquel pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT llerenaadrian pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT cabrerabibiana pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT mezquidagisela pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT loboantonio pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT gonzalezpintoana pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT diazcanejacovadongam pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT corripioiluminada pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT aguilareduardoj pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT bulbenaantoni pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT castrofornielesjosefina pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT vietaeduard pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT lafuenteamalia pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT massergi pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT parelladamara pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT saizruizjeronimo pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT cuestamanuelj pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT bernardomiguel pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject AT pharmacovigilancestudyinfirstepisodeofpsychosispsychopharmacologicalinterventionsandsafetyprofilesinthepepsproject |